- Home
- PULM vs CVM Comparison
PULM vs CVM Comparison
Compare PULM & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- CVM
- Stock Information
- Founded
- PULM 2003
- CVM 1983
- Country
- PULM United States
- CVM United States
- Employees
- PULM N/A
- CVM N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PULM Health Care
- CVM Health Care
- Exchange
- PULM Nasdaq
- CVM Nasdaq
- Market Cap
- PULM 20.5M
- CVM 18.1M
- IPO Year
- PULM N/A
- CVM 1987
- Fundamental
- Price
- PULM $4.71
- CVM $8.70
- Analyst Decision
- PULM
- CVM
- Analyst Count
- PULM 0
- CVM 0
- Target Price
- PULM N/A
- CVM N/A
- AVG Volume (30 Days)
- PULM 10.4K
- CVM 551.3K
- Earning Date
- PULM 08-06-2025
- CVM 08-14-2025
- Dividend Yield
- PULM N/A
- CVM N/A
- EPS Growth
- PULM N/A
- CVM N/A
- EPS
- PULM N/A
- CVM N/A
- Revenue
- PULM $369,000.00
- CVM N/A
- Revenue This Year
- PULM N/A
- CVM N/A
- Revenue Next Year
- PULM $134.88
- CVM N/A
- P/E Ratio
- PULM N/A
- CVM N/A
- Revenue Growth
- PULM N/A
- CVM N/A
- 52 Week Low
- PULM $1.78
- CVM $1.98
- 52 Week High
- PULM $10.40
- CVM $39.30
- Technical
- Relative Strength Index (RSI)
- PULM 32.51
- CVM 62.27
- Support Level
- PULM $4.65
- CVM $6.84
- Resistance Level
- PULM $5.09
- CVM $8.59
- Average True Range (ATR)
- PULM 0.28
- CVM 1.32
- MACD
- PULM -0.01
- CVM -0.14
- Stochastic Oscillator
- PULM 5.38
- CVM 54.55
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.